ID   MCF-7/SB-T-0035R
AC   CVCL_C0CU
SY   MCF7/SB-T-0035R
DR   cancercelllines; CVCL_C0CU
DR   Wikidata; Q112930091
RX   PubMed=29625142;
CC   Population: Caucasian.
CC   Characteristics: Generated by step-increasing drug concentration to 300 nm of SB-T-0035. Overexpresses ABCB1 which is amplified and inserted in chromosome 19 (PubMed=29625142; Direct_author_submission).
CC   Doubling time: ~25-30 hours (Direct_author_submission).
CC   Selected for resistance to: SB-T-0035 (Stony-Brooke Taxane 35).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Miscellaneous: Doubling time, ABCB1 status and STR profile from personal communication of Daniel, Petr.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 14
ST   D19S433: 13,14
ST   D21S11: 30
ST   D2S1338: 21,23
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 10,14
ST   FGA: 23,25
ST   TH01: 6
ST   TPOX: 9,12
ST   vWA: 14,15
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 10-09-24; Version: 7
//
RX   PubMed=29625142; DOI=10.1016/j.taap.2018.04.002; PMCID=PMC5937276;
RA   Jelinek M., Balusikova K., Daniel P., Nemcova-Furstova V.,
RA   Kirubakaran P., Jacek M., Wei L.-F., Wang X., Vondrasek J., Ojima I.,
RA   Kovar J.;
RT   "Substituents at the C3' and C3'N positions are critical for taxanes
RT   to overcome acquired resistance of cancer cells to paclitaxel.";
RL   Toxicol. Appl. Pharmacol. 347:79-91(2018).
//